Am. J. Respir. Crit. Care Med., Volume 162, Number 4, October 2000, 1455-1461

Prolonged Airway Activity and Improved Selectivity of Budesonide Possibly Due to Esterification

ANNA MILLER-LARSSON, P. JANSSON, A. RUNSTRÖM, and R. BRATTSAND

AstraZeneca R&D Lund, Lund, Sweden

We addressed the question of whether the prolonged local retention of the glucocorticoid (GC) budesonide (BUD) within airway tissue, due to reversible fatty acid esterification, is associated with protracted topical anti-inflammatory activity and improved airway selectivity, when compared with fluticasone propionate (FP). BUD or FP at 25 nmol/kg was administered intratracheally or subcutaneously to adrenalectomized rats, followed by lipopolysaccharide (LPS) intratracheal instillation. The trachea and main bronchi were lavaged 6 h after LPS, and tumor necrosis factor-alpha (TNF-) concentration and cell number in the lavage fluid were measured. Instilled 1 h before LPS, both GCs reduced TNF- by 70% (p < 0.05) and mononuclear cells by 55% (p < 0.01), with no reduction in neutrophils. Instilled 6 h before LPS, a significant reduction of TNF- (59%, p < 0.02) and mononuclear cells (47%, p < 0.05) was achieved only with BUD. After subcutaneous administration, no significant effects were observed. BUD did not exert higher systemic activity than FP, measured as plasma corticosterone suppression. In conclusion, BUD exerted a more prolonged topical anti-inflammatory activity, and a higher airway selectivity than FP, possibly because of its reversible fatty acid esterification within airway tissue. This may contribute to the high efficacy and safety of BUD in asthma, even with once-daily inhalation.

This article has been cited by other articles:

				K. Lexmuller, H. Gullstrand, B.-O. Axelsson, P. Sjolin, S. H. Korn, D. S. Silberstein, and A. Miller-Larsson Differences in Endogenous Esterification and Retention in the Rat Trachea between Budesonide and Ciclesonide Active Metabolite Drug Metab. Dispos., October 1, 2007; 35(10): 1788 - 1796. [Abstract] [Full Text] [PDF]

				H. Derendorf, R. Nave, A. Drollmann, F. Cerasoli, and W. Wurst Relevance of pharmacokinetics and pharmacodynamics of inhaled corticosteroids to asthma. Eur. Respir. J., November 1, 2006; 28(5): 1042 - 1050. [Abstract] [Full Text] [PDF]

				J. Winkler, G. Hochhaus, and H. Derendorf How the Lung Handles Drugs: Pharmacokinetics and Pharmacodynamics of Inhaled Corticosteroids Proceedings of the ATS, December 1, 2004; 1(4): 356 - 363. [Abstract] [Full Text] [PDF]

				S. Bozinovski, J. Jones, S.-J. Beavitt, A. D. Cook, J. A. Hamilton, and G. P. Anderson Innate immune responses to LPS in mouse lung are suppressed and reversed by neutralization of GM-CSF via repression of TLR-4 Am J Physiol Lung Cell Mol Physiol, April 1, 2004; 286(4): L877 - L885. [Abstract] [Full Text] [PDF]

				S. Rohatagi, S. Appajosyula, H. Derendorf, S. Szefler, R. Nave, K. Zech, and D. Banerji Risk-Benefit Value of Inhaled Glucocorticoids: A Pharmacokinetic/Pharmacodynamic Perspective J. Clin. Pharmacol., January 1, 2004; 44(1): 37 - 47. [Abstract] [Full Text] [PDF]

				M. J. TOBIN Asthma, Airway Biology, and Allergic Rhinitis in AJRCCM 2000 Am. J. Respir. Crit. Care Med., November 1, 2001; 164(9): 1559 - 1580. [Full Text] [PDF]

				M. Jendbro, C.-J. Johansson, P. Strandberg, H. Falk-Nilsson, and S. Edsbäcker Pharmacokinetics of Budesonide and Its Major Ester Metabolite after Inhalation and Intravenous Administration of Budesonide in the Rat Drug Metab. Dispos., April 13, 2001; 29(5): 769 - 776. [Abstract] [Full Text]